Skip to Main content Skip to Navigation
Journal articles

Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma

Abstract : Malignant melanoma is an aggressive cancer known for its notorious resistance to most current therapies. The basic helix-loop-helix microphthalmia transcription factor (MITF) is the master regulator determining the identity and properties of the melanocyte lineage, and is regarded as a lineage-specific 'oncogene' that has a critical role in the pathogenesis of melanoma. MITF promotes melanoma cell proliferation, whereas sustained supression of MITF expression leads to senescence. By combining chromatin immunoprecipitation coupled to high throughput sequencing (ChIP-seq) and RNA sequencing analyses, we show that MITF directly regulates a set of genes required for DNA replication, repair and mitosis. Our results reveal how loss of MITF regulates mitotic fidelity, and through defective replication and repair induces DNA damage, ultimately ending in cellular senescence. These findings reveal a lineage-specific control of DNA replication and mitosis by MITF, providing new avenues for therapeutic intervention in melanoma. The identification of MITF-binding sites and gene-regulatory networks establish a framework for understanding oncogenic basic helix-loop-helix factors such as N-myc or TFE3 in other cancers.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02530755
Contributor : Bertolotto-Ballotti Bertolotto-Ballotti <>
Submitted on : Friday, April 3, 2020 - 11:00:16 AM
Last modification on : Wednesday, October 14, 2020 - 4:24:18 AM

Links full text

Identifiers

Collections

Citation

T Strub, S. Giuliano, T Ye, C Bonet, C. Keime, et al.. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene, Nature Publishing Group, 2011, 30 (20), pp.2319-2332. ⟨10.1038/onc.2010.612⟩. ⟨inserm-02530755⟩

Share

Metrics

Record views

31